Venus Remedies bags marketing nod for generic cancer drugs from Uzbekistan, Palestine

Published On 2023-02-22 10:00 GMT | Update On 2023-02-22 11:49 GMT

Mumbai: Venus Remedies Limited has received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine. Having over 800 marketing authorisations worldwide, the company is making big strides by now extending its footprint in Central Asia and Middle East with the marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine.Venus Remedies...

Mumbai: Venus Remedies Limited has received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine. Having over 800 marketing authorisations worldwide, the company is making big strides by now extending its footprint in Central Asia and Middle East with the marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine.

Venus Remedies is expected to launch these drugs in Uzbekistan and Palestine in the next financial year.

Venus Remedies Joint Managing Director Dr Manu Chaudhary said, “It is a proud moment for all of us, a significant step towards delivering healthcare solutions that are effective and have a positive impact on patients’ lives. Our mission is to make cancer treatment accessible to everyone and improve outcomes. The approval of these products brings us closer to achieving this goal.”

She said the marketing authorisations would help Venus Remedies further strengthen its oncology portfolio and improve its presence in the oncology space. “The two markets offer a great opportunity to us and we are aiming at capturing a sizeable share in these markets through the three cancer drugs in the very first year of their launch. We will continue to invest in our generic drug portfolio and expand to new geographies,” said Chaudhary.

Panchkula-based Venus Remedies Ltd is among the 10 leading fixed-dosage injectable manufacturers in the world. Having presence in 80 countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, Middle East, Latin America and Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European-GMP, WHO-GMP and Latin American GMP(INVIMA), among others.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Venus Remedies bags marketing nod for generic cancer drugs from Uzbekistan, Palestine

Similar News